Wayne Rawlins, MD

Wayne Rawlins, MD, is council chair for the Medical Director Advisory Council at the National Alliance of Healthcare Purchaser Coalitions.

Articles by Wayne Rawlins, MD

What Health Inequities Are Really Costing Your Company: Wayne Rawlins, MD

ByGiuliana Grossi,Wayne Rawlins, MD

March 5th 2026

Health inequities add $360 billion yearly; see how employers uncover disparities in claims, rethink deductibles, and invest in prevention to curb costs.

Latest Updated Articles

What Health Inequities Are Really Costing Your Company: Wayne Rawlins, MD
March 5th 2026

Wayne Rawlins, MD

Articles by Wayne Rawlins, MD

What Health Inequities Are Really Costing Your Company: Wayne Rawlins, MD

Latest Updated Articles

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Wayne Rawlins, MD

Articles by Wayne Rawlins, MD

What Health Inequities Are Really Costing Your Company: Wayne Rawlins, MD

Latest Updated Articles

Trending on AJMC

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Tec-Dara Shows MRD-Negative, PFS Benefit in High-Risk Myeloma, But Longer Follow-Up Needed: Rahul Banerjee, MD

Early Treatment Succeeds in CRC With Next Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

Kazia Therapeutics Discusses Shift for Paxalisib Into Triple-Negative Breast Cancer